Long-term methimazole therapy in Graves' hyperthyroidism and adverse reactions: a Danish multicenter study.
Jesper KarmisholtStine Linding AndersenI Bulow-PedersenA KrejbjergB NygaardA CarléPublished in: European thyroid journal (2022)
With this study, we report the frequency, timing of occurrence, and characteristics of adverse drug reactions when treating GH with the ATD drug methimazole for up to 48 months. Long-term low-dose methimazole treatment can be a cost-effective and straightforward treatment option if adverse drug reactions such as severe hepatic and bone marrow affection are kept in mind.